NEW YORK, Jan. 9, 2020 /PRNewswire/ -- Tacitus Therapeutics, a clinical-stage company, has launched in collaboration with the Mount Sinai Health System to develop stem cell therapies initially targeting blood cancers and related clotting disorders. Their first therapy, HSC100, currently is being investigated in a Phase I clinical trial1.
Tacitus is building upon technology developed by and exclusively licensed from Mount Sinai. Based on research by scientific co-founders Ronald Hoffman, M.D., and Camelia Iancu-Rubin, Ph.D., the technology includes proprietary cell expansion, differentiation and engineering methods. Together, these methods manufacture healthy cells that overcome the limitations of traditional allogeneic, or donor, cell transplantations.
Blood cancers comprise about 10% of new cancer cases in the U.S. each year, and almost 60,000 people die from blood cancer complications annually. Most blood cancers start in the bone marrow, where blood is produced. A common therapy for such blood cancers is a hematopoietic stem cell (HSC) treatment or, as more commonly referred to, bone marrow transplantation. In this process, doctors infuse healthy HSCs into the patient's bloodstream, where they migrate to the bone marrow to grow or engraft.
HSCs for this process can be collected from bone marrow, circulating blood, or umbilical cord blood (CB) of healthy donors. While HSC transplants are common, significant barriers to success exist, including high levels of graft-versus-host disease, low numbers of healthy cells obtained from CB, and increased risk of bleeding due to delayed megakaryocyte, or platelet, engraftment.
Hoffman and Iancu-Rubin are pioneers of bone marrow cell therapy treatments, and development of this technology was enabled by the New York State Stem Cell Science program, NYSTEM. As a New York State Department of Health initiative, NYSTEM awarded a $1 million grant to Hoffman in 2010 that supported the original research underpinning this platform technology. In 2015, NYSTEM awarded Hoffman and Iancu-Rubin an $8 million grant to translate the technology from the laboratory into the clinic, where it is currently in clinical trial1.
Hoffman also serves as Director of the Myeloproliferative Disorders Research Program and Professor of Medicine (Hematology and Medical Oncology) and Iancu-Rubin is Associate Professor of Pathology at the Icahn School of Medicine and Director of the Cellular Therapy Laboratory at Mount Sinai Hospital.
"Promising discoveries by Mount Sinai scientific thought leaders may lead to new, essential cell-based therapies that will broadly benefit patients," said Erik Lium, Executive Vice President and Chief Commercial Innovation Officer, Mount Sinai Innovation Partners. "We're pleased to be collaborating with Tacitus to launch the next stage of development for these technologies."
"Tacitus is committed in its mission to advance next-generation cell therapies with curative potential," said Carter Cliff, CEO of Tacitus. "Based on our founders' solid foundation of research, we are translating these discoveries into broad clinical practice as we look to dramatically improve the standard of care for patients with life-threatening conditions."
HSC100 is an investigational therapy based on allogeneic hematopoietic stem cells (HSC) expanded from umbilical cord blood. HSC100 is being investigated currently in an open-label Phase I clinical trial1 in the United States for treatment of hematological malignancies. The success of unmanipulated cord blood as a source of stem cells has been hampered by the small number of stem cells present in a single cord, leading to delayed engraftment and frequent graft failure. Our proprietary technology includes the use of an epigenetic modifier, valproic acid, to expand the number and the quality of HSCs found in cord blood collections. For more information on HSC100 clinical trials, please visit http://www.clinicaltrials.gov.
1ClinicalTrials.gov identifier NCT03885947.
About Tacitus Therapeutics
Tacitus Therapeutics is a clinical-stage biotechnology company developing advanced medicines for treatment of blood cancers, immune disorders and other intractable disease conditions. Our mission is to pioneer best-in-class therapies using proprietary cell expansion, differentiation and engineering platform technologies that overcome the limitations of traditional cell transplantation. Initial targets include a lead clinical program (HSC100) investigating the treatment of blood cancers, followed by preclinical programs to address clotting disorders and other serious unmet medical needs. For additional information, please visit http://www.tacitustherapeutics.com.
About Mount Sinai Health System
The Mount Sinai Health System is New York City's largest integrated delivery system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai's vision is to produce the safest care, the highest quality, the highest satisfaction, the best access and the best value of any health system in the nation. The Health System includes approximately 7,480 primary and specialty care physicians; 11 joint-venture ambulatory surgery centers; more than 410 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. The Icahn School of Medicine is one of three medical schools that have earned distinction by multiple indicators: ranked in the top 20 by U.S. News & World Report's "Best Medical Schools", aligned with a U.S. News & World Report's "Honor Roll" Hospital, No. 12 in the nation for National Institutes of Health funding, and among the top 10 most innovative research institutions as ranked by the journal Nature in its Nature Innovation Index. This reflects a special level of excellence in education, clinical practice, and research. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report's "Honor Roll" of top U.S. hospitals; it is one of the nation's top 20 hospitals in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Geriatrics, Gynecology, Nephrology, Neurology/Neurosurgery, and Orthopedics in the 2019-2020 "Best Hospitals" issue. Mount Sinai's Kravis Children's Hospital also is ranked nationally in five out of ten pediatric specialties by U.S. News & World Report. The New York Eye and Ear Infirmary of Mount Sinai is ranked 12th nationally for Ophthalmology, Mount Sinai St. Luke's and Mount Sinai West are ranked 23rd nationally for Nephrology and 25th for Diabetes/Endocrinology, and Mount Sinai South Nassau is ranked 35th nationally for Urology. Mount Sinai Beth Israel, Mount Sinai St. Luke's, Mount Sinai West, and Mount Sinai South Nassau are ranked regionally. For more information, visit http://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.
About Mount Sinai Innovation Partners (MSIP)
MSIP is responsible for driving the real-world application and commercialization of Mount Sinai discoveries and inventions and the development of research partnerships with industry. Our aim is to translate discoveries and inventions into health care products and services that benefit patients and society. MSIP is accountable for the full spectrum of commercialization activities required to bring Mount Sinai inventions to life. These activities include evaluating, patenting, marketing and licensing new technologies building research, collaborations and partnerships with commercial and nonprofit entities, material transfer and confidentiality, coaching innovators to advance commercially relevant translational discoveries, and actively fostering an ecosystem of entrepreneurship within the Mount Sinai research and health system communities. For more information, please visit http://www.ip.mountsinai.orgor find MSIP onLinkedIn, Twitter, Facebook,Medium, and YouTube.
Mount Sinai Cynthia Cleto Mount Sinai Innovation Partners (646) 605-7359 firstname.lastname@example.org
Tacitus TherapeuticsJoleen RauRau Communications(608) email@example.com
SOURCE Tacitus Therapeutics
- City of Hope to buy Cancer Treatment Centers of America for $390M - Modern Healthcare - December 9th, 2021
- The lung game: is hyperbaric oxygen therapy any good? - Financial Times - December 9th, 2021
- Cell Culture Media Market is predicted to grow from US$ 2.6 Bn in 2020 to over US$ 5.6 Bn by 2031 - PRNewswire - December 9th, 2021
- It is imperative to reduce the cost of cancer treatment: Ramesh Ramadurai, MD, 3M India - ETHealthworld.com - December 9th, 2021
- COVID: How bad is the omicron variant? Q&A on what new research is telling us - The Denver Post - December 9th, 2021
- What Are New Medical Solutions That Can Help Treat Patients? - iLounge - November 22nd, 2021
- Slidell mom with months to live, couldn't afford to fight 'very treatable' cancer - WWLTV.com - November 22nd, 2021
- Cell and Gene Therapy Market to reach US$ 47,095.2 Mn by end of 2028, Says Coherent Market Insights - PRNewswire - November 22nd, 2021
- FMQs: Senior Glasgow doctor warns claims doctors act in secret or conceal information could damage public confidence as Andrew Slorance widow claims... - November 22nd, 2021
- Former Tranmere player Gary Stevens' son dies after battle with leukaemia - The Chester Standard - November 22nd, 2021
- Braeden Lichti - Investing in Precision Medicine to Yield New Treatments for Neurodegenerative Diseases - PRNewswire - November 22nd, 2021
- Global Cancer Therapy Market Expected to Reach $268 Billion In 2026, With A CAGR Of 9.15% - PRNewswire - November 22nd, 2021
- Indiana's top doctors frustrated about the state's COVID-19 vaccination rate - 953mnc.com - August 31st, 2021
- Should You Get a COVID Booster Shot? Our Doctor Explains - Articles and Videos, COVID-19, Featured, Health Topics - Hackensack Meridian Health - August 31st, 2021
- OpRegen: tackling the leading cause of blindness with cell replacement - Clinical Trials Arena - August 31st, 2021
- I blamed stress for my three-month period but it turned out to be much more sinister... - The Sun - August 31st, 2021
- New fault lines emerge in Car-T therapy - Vantage - August 31st, 2021
- When aid-in-dying means you have to go before youre ready - Monterey Herald - August 31st, 2021
- Dr. Death Season 1 Review: Truth continues to be stranger than fiction. - Times of India - August 31st, 2021
- Circulating Tumor Cells (CTC) Diagnostics Market is expected to Account for Over US$ 9.5 Million in - PharmiWeb.com - August 31st, 2021
- COVID-19 in children with cancer: Severe disease and disrupted treatment - Markets Insider - August 31st, 2021
- Sophomore saves sister's life with stem cell donation - University of Miami - August 5th, 2021
- Myelodysplastic Syndrome Treatment Options - Healthline - August 5th, 2021
- Gold River Productions, Inc. (GRPS) Appoints Michael Berkowitz to spearhead the Rejuvenation Division with StemSpa - Yahoo Finance - August 5th, 2021
- Colin Jackson health: Im in constant pain Athlete to undergo stem cell therapy to help - Express - August 5th, 2021
- The Basics of MDS: Diagnosis and Staging - Curetoday.com - August 5th, 2021
- Blood donation clinic will honour life of Jocelyn McGlynn - Chatham Daily News - August 5th, 2021
- Pharming Group reports financial results for the first half of 2021 - PRNewswire - August 5th, 2021
- Symptoms of seizures: Early signs, post-seizure, and more - Medical News Today - August 5th, 2021
- Lymph nodes: Purpose, location, and disease warning signs - Medical News Today - June 8th, 2021
- Teesside baby will be third in country to have ground breaking complex cancer treatment - Teesside Live - June 8th, 2021
- Brave Nathaniel Nabena, 9, all smiles as he has life-saving procedure - thanks to you - The Mirror - June 8th, 2021
- Local veterinary clinics offer integrated care options for pets - williamsonherald.com - June 8th, 2021
- Blood cancer and leukaemia: UAE oncologist urges public to spot the symptoms - The National - June 8th, 2021
- Replotting the human: the thorny ethics of growing babies outside the womb - Prospect - June 8th, 2021
- Crossroads of life: Jordan Reed's journey through concussions, injuries and post-NFL healing - The Athletic - June 8th, 2021
- B-cell acute lymphoblastic leukemia: What to know - Medical News Today - May 28th, 2021
- Chronic lymphocytic leukemia and stomach pain: What is the link? - Medical News Today - May 28th, 2021
- Top 12 Disruptive Gene and Cell Therapy Technologies Announced - GlobeNewswire - May 28th, 2021
- BlueRock and Senti Collaborate to Build Smarter, Disease-Fighting Cell Therapies - BioSpace - May 28th, 2021
- Living with blood cancer - Lara Said - Times of Malta - May 28th, 2021
- 3D Printed Stem Cells Could Revolutionize Neuroscience, Aid Treatment and Understanding of Neural Diseases - Science Times - May 28th, 2021
- In the War on Cancer, Science Is Winning - The Wall Street Journal - May 28th, 2021
- Whats Causing Black Fungus? Here Is What The Doctors Have To Say - The Logical Indian - May 28th, 2021
- University of Pittsburgh Won't Explain its Planned Parenthood Ties | Opinion - Newsweek - May 28th, 2021
- Trial treatment with a mythologically-inspired name saves life of young man diagnosed with multiple myeloma - Neos Kosmos - May 28th, 2021
- An unusual addition to Californias 2022 ballot - CalMatters - May 28th, 2021
- Stem Cell Therapy Los Angeles - Darrow Stem Cell Institute - February 14th, 2021
- Stem Cell Transplants: A Lifesaving Treatment for Cancer ... - February 14th, 2021
- Smart Stem Cells Made From Fat Have the Power to Heal - Freethink - February 14th, 2021
- Are Covid-19 vaccines safe for cancer patients? Here is what cancer experts say - CNN - February 14th, 2021
- The race to treat a rare, fatal syndrome may help others with common disorders like diabetes - Science Magazine - February 14th, 2021
- Arlo's Army needs stem cell donor as mum begs for help to save three-year-old's life - Glasgow Live - February 14th, 2021
- Arlo's Army: mum opens up on heartbreaking decision to make 3-year-old sick to save his life - Glasgow Live - February 14th, 2021
- Bone marrow transplant shows signs of curing brave little boy with one in a million condition - Shields Gazette - February 14th, 2021
- Canada's blood supply has a diversity problem and people are dying because of it - CBC.ca - February 2nd, 2021
- State-of-the-Art Treatments Garner University Foot and Ankle Institute Multiple Top Doctor Awards - Yahoo Finance - February 2nd, 2021
- Dean Tracy Johnson seeks to diversify the pipeline of future scientists and doctors - UCLA Newsroom - February 2nd, 2021
- Transforming optimism: finding new ways to treat rare cancers - Cancer Research UK - Science Blog - February 2nd, 2021
- Family of Belfast woman Eimear Gooderham (25) share memories and dealing with grief in special UTV programme - Belfast Telegraph - February 2nd, 2021
- Doctor: COVID-19 cases will continue to slowly go down, but were not out of the woods - Yahoo Money - January 23rd, 2021
- Global Precision Medicine Market With COVID 19 Impact Analysis| Leading Players In-depth Analysis Research Report Foresight to 2027 - KSU | The... - January 23rd, 2021
- Leading Urologist Doubles Down on CaverStem Regenerative Stem Cell Procedure for Treatment of Erectile Dysfunction in Men - PRNewswire - January 22nd, 2021
- Sisters who organised an Ilkley fundraising ball are to be honoured - Wharfedale Observer - January 22nd, 2021
- Medical Doctor: Roes Overlooking of the Consensus of Societal Morality and Science Reverberates to This Day - National Catholic Register - January 22nd, 2021
- DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL)... - January 22nd, 2021
- Seattle researchers find clues for treatments that could eliminate HIV in infected patients - GeekWire - January 14th, 2021
- Flow Cytometry Market is Projected to Reach a Value of US$8100 Mn by the End of 2025 - KSU | The Sentinel Newspaper - January 14th, 2021
- Doctors diagnosed a Suffolk teen with a rare condition. Now, his mom is part of the solution - 13newsnow.com WVEC - January 12th, 2021
- Cassville club assists 2 families as they recover from illness - telegraphherald.com - January 12th, 2021
- The 26 billion-dollar startups to watch that are revolutionizing healthcare in 2021 - Business Insider - January 12th, 2021
- Global Precision Medicine Market 2020 Overview By Size, Share, Trends, Growth Factors and Leading Players With Detailed Analysis of Industry Structure... - January 12th, 2021
- More than 250 articles and a book later, the Valley Doctor bids adieu - San Lorenzo Valley Press-Banner - January 12th, 2021
- Groundbreaking Treatment for Severe COVID-19 Using Stem Cells It's Like Smart Bomb Technology in the Lung - SciTechDaily - January 5th, 2021
- New combo therapy offered against refractory T-cell lymphoma - Korea Biomedical Review - January 5th, 2021
- Hair Growth Treatment Secrets Bollywood Will Never Tell You About - Times of India - January 5th, 2021
- Are metabolic hormones the next frontier in cancer treatment? - MedCity News - January 5th, 2021
- Limerick toddler to wait six months for trial cancer treatment after family raises over 400,000 - Extra.ie - January 5th, 2021
- West Lothian mum fighting for her life after back pain turned out to be terminal blood cancer - Edinburgh Live - January 5th, 2021
- MorphoSys and Incyte Announce the Acceptance of the Swissmedic Marketing Authorization Application for Tafasitamab - Yahoo Finance UK - January 5th, 2021